Product Pathways - PI3K / Akt Signaling
SignalSilence® PTEN siRNA I #6251
|Transfection||H (M) (R)|
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells, transfected with non-targeted siRNA (-) or SignalSilence® PTEN siRNA I (+) using PTEN Antibody #9552 and p42 MAP Kinase (Erk2) Antibody #9108. The PTEN antibody confirms silencing of PTEN expression, while the p42 MAPK antibody is used to control for loading and specificity of PTEN siRNA.
SignalSilence® PTEN siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit PTEN expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Directions for Use
CST recommends transfection with 100 nM PTEN siRNA I 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
PTEN (phosphatase and tensin homologue deleted on chromosome ten), also referred to as MMAC (mutated in multiple advanced cancers) phosphatase, is a tumor suppressor implicated in a wide variety of human cancers (1). PTEN encodes a 403 amino acid polypeptide originally described as a dual-specificity protein phosphatase (2). The main substrates of PTEN are inositol phospholipids generated by the activation of the phosphoinositide 3-kinase (PI3K) (3). PTEN is a major negative regulator of the PI3K/Akt signaling pathway (1,4,5). PTEN possesses a carboxy-terminal, noncatalytic regulatory domain with three phosphorylation sites (Ser380, Thr382, and Thr383) that regulate PTEN stability and may affect its biological activity (6,7). PTEN regulates p53 protein levels and activity (8) and is involved in G protein-coupled signaling during chemotaxis (9,10).
- Cantley, L.C. and Neel, B.G. (1999) Proc Natl Acad Sci USA 96, 4240-5.
- Myers, M.P. et al. (1997) Proc Natl Acad Sci USA 94, 9052-7.
- Myers, M.P. et al. (1998) Proc Natl Acad Sci USA 95, 13513-8.
- Wan, X. and Helman, L.J. (2003) Oncogene 22, 8205-11.
- Wu, X. et al. (1998) Proc Natl Acad Sci USA 95, 15587-91.
- Vazquez, F. et al. (2000) Mol Cell Biol 20, 5010-8.
- Torres, J. and Pulido, R. (2001) J Biol Chem 276, 993-8.
- Freeman, D.J. et al. (2003) Cancer Cell 3, 117-30.
- Funamoto, S. et al. (2002) Cell 109, 611-23.
- Iijima, M. and Devreotes, P. (2002) Cell 109, 599-610.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6538 SignalSilence® PTEN siRNA II
- 9552 PTEN Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.